6-pyridin-3-yl-3,4-dihydro-1h-quinolin-2-one derivatives and related compounds as inhibitors of the human aldosterone synthase CYP11B2
The invention provides compounds of the general formula (I) which are inhibitors of the human aldosterone synthase, and also pharmaceutical compositions containing these compounds, and the use of these compounds and other heteroaryl substituted quinolinone derivatives for the treatment of hyperaldosteronism and/or disorders or diseases that are mediated by 11 β-hydroxylase (CYP11 B1).
1. A compound of formula (I):
wherein:
Z is C═O or C═S;
U is CR 5 R 6 , NR 7 , O or S;
X is CR 5 R 6 , NR 7 , O, or S;
A is CR 8 R 9
b is 0 or 1;
n is 0;
m is 0 or 1;
provided that not more than one of U and X is NR 7 , O, or S;
wherein, when m is 1, the bond between U and X is single bond;
Het is a ring system containing 1 or 2 rings, where the or at least one of the rings is aromatic and contains 5 or 6 ring atoms, of which at least one is nitrogen, and the other ring of the 2 rings can be saturated or unsaturated and comprises from 5 to 7 ring atoms; while the ring system can contain additional 1 to 5 heteroatoms selected from the group consisting of N, S, and O, provided that not more than two heteroatoms are selected from the group consisting of S and O; and the ring system can be substituted by from one to four substituents R 11 ,
R 1 and R 2 form, together with the atoms to which they are bonded, an unsaturated nitrogen-containing five membered to seven membered ring comprising 1 or 2 unsaturated bonds and may, in addition to the nitrogen atom to which the R 1 group is bonded, also contain a hetero atom or a heteroatom-containing group selected from the group consisting of O, S and NR 7 , and can be substituted by from one to four substituents R 12 ;
R 3 and R 4 are independently selected from the group consisting of H, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-7 cycloalkyl, C 5-7 cycloalkenyl, C 1-4 alkoxy, C 1-4 alkylcarbonyl, C 1-4 alkoxycarbonyl, C 1-4 alkylsulfonyl, which in each case can be partially or completely halogenated with independent halogen atoms or can be substituted by from one to three substituents R a , wherein R a is independently selected from the group consisting of optionally partially or completely halogenated C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylthio, and C 1-4 alkylcarbonyl and also hydroxyl, nitro, and cyano, or can be partially or completely halogenated with independent halogen atoms; aryl C 1-4 alkyl, aryl C 0-4 alkylsulfonyl, heterocyclyl C 1-4 alkyl, which can in each case be substituted on the ring or at least on one ring by from one to four substituents R b , wherein R b is selected from the group consisting of C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylthio, C 1-4 alkylcarbonyl, C 1-4 alkylsulfonyl, whose alkyl moieties may be partially or completely halogenated with independent halogen atoms, halogen, hydroxyl, nitro, cyano, —NR c 2 , —CONR c 2 , and SO 2 NR c 2 , wherein R c is independently selected from the group consisting of H and C 1-4 alkyl; halogen, hydroxyl, nitro, cyano, —NR c 2 , —CONR c 2 , and —SO 2 NR c 2 ;
R 5 and R 6 are independently selected from the group consisting of H, C 1-4 alkyl, C 3-7 cycloalkyl, hydroxyl C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkoxycarbonyl, C 1-4 alkylthio, whose alkyl moieties can be partially or completely halogenated with independent halogen atoms; halogen, hydroxyl, nitro, cyano, —NR c 2 , and NR c COR d , and R d is selected from the group consisting of C 1-4 alkyl, C 3-7 cycloalkyl, C 1-4 alkoxy, whose alkyl moieties can be partially or completely halogenated with independent halogen atoms, and wherein R 5 or R 6 may be bonded to a carbon atom forming part of a double bond,
R 7 is selected from the group consisting of H, C 1-4 alkyl, and C 3-7 cycloalkyl, which in each case can be substituted by from one to three substituents R a , or can be partially or completely halogenated with independent halogen atoms; and aryl C 1-4 alkyl, which can be substituted on the ring or at least on one ring by from one to four substituents R b ;
R 8 is phenyl;
R 9 is H or hydroxyl;
R 10 is selected from the group consisting of H; C 1-4 alkyl, C 3-7 cycloalkyl, which in each case can be substituted by from one to three substituents R a , or can be partially or completely halogenated with independent halogen atoms; aryl, aryl C 1-4 alkyl, heterocyclyl, and heterocyclyl C 1-4 alkyl, each of which can be substituted on the or at least one ring by from one to four substituents R b ;
R 11 is independently selected from the group consisting of C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-7 cycloalkyl, C 5-7 cycloalkenyl, C 1-4 alkoxy, C 1-4 alkylthio, C 1-4 alkylcarbonyl, C 1-4 alkoxycarbonyl, C 1-4 alkylsulfonyl, which can in each case be substituted by from one to three substituents R a , or can be partially or completely halogenated with independent halogen atoms; aryl, heterocyclyl, aryl C 0-4 alkylsulfonyl, aryl C 1-4 alkyl, and heterocyclyl C 1-4 alkyl, which can in each case be substituted on the ring or at least on one ring by from one to four substituents R b , halogen, hydroxyl, nitro, cyano, —NR c 2 , —CONR c 2 , and —SO 2 NR c 2 ; and
R 12 is independently selected from the group consisting of C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-7 cycloalkyl, C 5-7 cycloalkenyl, which can in each case be substituted by from one to three substituents R a , or can be partially or completely halogenated with independent halogen atoms; aryl, heterocyclyl, aryl C 1-4 alkyl, and heterocyclyl C 1-4 alkyl, which can in each case be substituted on the ring or at least on one ring by from one to four substituents R b ; optionally partially or completely halogenated C 1-4 alkoxy, hydroxyl, halogen, nitro, cyano, and NR c 2 when R 12 is bonded to a carbon atom;
or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1 , wherein Z is C═O, or a pharmaceutically acceptable salt thereof.
3. A compound according to claim 1 , wherein U is S or CR 5 R 6 , wherein R 5 and R 6 are independently selected from H and C 1-4 alkyl, X is CH 2 , or a pharmaceutically acceptable salt thereof.
4. A compound according to claim 1 , wherein the unsaturated nitrogen containing ring is an unsubstituted 5- or 6-membered ring having one or two unsaturated bond(s) and no further heteroatom, or a pharmaceutically acceptable salt thereof.
5. A compound according to claim 1 , wherein Het is for pyridinyl, isoquinolinyl, pyrimidinyl or imidazolyl, optionally substituted with a substituent R 11 , wherein R 11 is defined as in claim 1 , or a pharmaceutically acceptable salt thereof.
6. A compound according to claim 1 selected from
8-Pyridin-3-yl-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one
9-Pyridin-3-yl-1,2,6,7-tetrahydro-5H-pyrido[3,2,1-ij]quinolin-3-one
8-(5-Methoxypyridin-3-yl)-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one
8-Isoquinolin-4-yl-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one
9-(5-Methoxypyridin-3-yl)-1,2,6,7-tetrahydro-5H-pyrido[3,2,1-ij]quinolin-3-one
9-Isoquinolin-4-yl-1,2,6,7-tetrahydro-5H-pyrido[3,2,1-ij]quinolin-3-one
8-Pyridin-3-yl-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinoline-4-thione
8-(5-Hydroxypyridin-3-yl)-1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-one
6,6-Dimethyl-8-pyridin-3-yl-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one
8-(5-Ethoxypyridin-3-yl)-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one
8-(5-Trifluoromethylpyridin-3-yl)-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one
8-(5-Fluoropyridin-3-yl)-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one
8-Imidazol-1-yl-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one
8-Pyridin-4-yl-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one
8-Pyrimidin-5-yl-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one
8-(Pyridin-4-carbonyl)-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one
8-(Pyridin-3-carbonyl)-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one
8-(5-Phenylpyridin-3-yl)-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one
8-(5-Isopropoxypyridin-3-yl)-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one
8-(1-Imidazol-1-yl-ethyl)-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one
8-[5-(4-Fluorophenyl)pyridin-3-yl]-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one
8-[5-(3-Fluorophenyl)pyridin-3-yl]-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one
8-[5-(4-Methoxyphenyl)pyridin-3-yl]-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one
8-[5-(3-Methoxyphenyl)pyridin-3-yl]-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one
8-[5-(2-Fluorophenyl)pyridin-3-yl]-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one
8-[5-(3-Trifluoromethylphenyl)pyridin-3-yl]-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one
8-[5-(3,4-Difluorophenyl)pyridin-3-yl]-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one
8-[5-(3-Trifluoromethoxyphenyl)pyridin-3-yl]-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]-quinolin-4-one
8-[5-(2-Methoxyphenyl)pyridin-3-yl]-1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one
or a pharmaceutically acceptable salt thereof.
7. A compound of formula (I):
wherein:
Z is C═O or C═S;
U is CR 5 R 6 , NR 7 , O or S;
X is CR 5 R 6 , NR 7 , O, or S;
b is 0;
n is 0;
m is 0 or 1;
provided that not more than one of U and X is NR 7 , O, or S;
wherein, when m is 1, the bond between U and X is single bond;
Het is a ring system containing 2 rings, where at least one of the rings is aromatic and contains 5 or 6 ring atoms, of which at least one is nitrogen, and the other ring can be saturated or unsaturated and comprises from 5 to 7 ring atoms; while the ring system can contain additional 1 to 5 heteroatoms selected from the group consisting of N, S, and O, provided that not more than two heteroatoms are selected from the group consisting of S and O; and the ring system can be substituted by from one to four substituents R 11 ,
R 1 is selected from the group consisting of H; C 1-4 alkyl; C 2-4 alkenyl; C 3-7 cycloalkyl; C 1-4 alkylcarbonyl; and C 1-4 alkoxycarbonyl; each of which can be substituted by from one to three substituents R a , wherein R a is independently selected from the group consisting of optionally partially or completely halogenated C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylthio, and C 1-4 alkylcarbonyl and also hydroxyl, nitro, and cyano, or can be partially or completely halogenated with independent halogen atoms; aryl C 1-4 alkyl and heterocyclyl C 1-4 alkyl, which can in each case be substituted on the ring or at least on one ring by from one to four substituents R b , wherein R b is selected from the group consisting of C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylthio, C 1-4 alkylcarbonyl, C 1-4 alkylsulfonyl, whose alkyl moieties may be partially or completely halogenated with independent halogen atoms, halogen, hydroxyl, nitro, cyano, —NR c 2 , —CONR c 2 , and SO 2 NR c 2 , wherein R c is independently selected from the group consisting of H and C 1-4 alkyl;
R 2 , R 3 and R 4 are independently selected from the group consisting of H, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-7 cycloalkyl, C 5-7 cycloalkenyl, C 1-4 alkoxy, C 1-4 alkylcarbonyl, C 1-4 alkoxycarbonyl, C 1-4 alkylsulfonyl, which in each case can be substituted by from one to three substituents R a , or can be partially or completely halogenated with independent halogen atoms; aryl C 1-4 alkyl, aryl C 0-4 alkylsulfonyl, heterocyclyl C 1-4 alkyl, which can in each case be substituted on the ring or at least on one ring by from one to four substituents R b ; halogen, hydroxyl, nitro, cyano, —NR c 2 , —CONR c 2 , and —SO 2 NR c 2 ;
R 5 and R 6 are independently selected from the group consisting of H, C 1-4 alkyl, C 3-7 cycloalkyl, hydroxyl C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkoxycarbonyl, C 1-4 alkylthio, whose alkyl moieties can be partially or completely halogenated with independent halogen atoms; halogen, hydroxyl, nitro, cyano, —NR c 2 , and NR c COR d , and R d is selected from the group consisting of C 1-4 alkyl, C 3-7 cycloalkyl, C 1-4 alkoxy, whose alkyl moieties can be partially or completely halogenated with independent halogen atoms, and wherein R 5 or R 6 may be bonded to a carbon atom forming part of a double bond,
R 7 is selected from the group consisting of H, C 1-4 alkyl, and C 3-7 cycloalkyl, which in each case can be substituted by from one to three substituents R a , or can be partially or completely halogenated with independent halogen atoms; and aryl C 1-4 alkyl, which can be substituted on the ring or at least on one ring by from one to four substituents R b ;
R 10 is selected from the group consisting of H; C 1-4 alkyl, C 3-7 cycloalkyl, which in each case can be substituted by from one to three substituents R a , or can be partially or completely halogenated with independent halogen atoms; aryl, aryl C 1-4 alkyl, heterocyclyl, and heterocyclyl C 1-4 alkyl, each of which can be substituted on the or at least one ring by from one to four substituents R b ;
R 11 is independently selected from the group consisting of C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-7 cycloalkyl, C 5-7 cycloalkenyl, C 1-4 alkoxy, C 1-4 alkylthio, C 1-4 alkylcarbonyl, C 1-4 alkoxycarbonyl, C 1-4 alkylsulfonyl, which can in each case be substituted by from one to three substituents R a , or can be partially or completely halogenated with independent halogen atoms; aryl, heterocyclyl, aryl C 0-4 alkylsulfonyl, aryl C 1-4 alkyl, and heterocyclyl C 1-4 alkyl, which can in each case be substituted on the ring or at least on one ring by from one to four substituents R b , halogen, hydroxyl, nitro, cyano, —NR c 2 , —CONR c 2 , and —SO 2 NR c 2 ; and
R 12 is independently selected from the group consisting of C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-7 cycloalkyl, C 5-7 cycloalkenyl, which can in each case be substituted by from one to three substituents R a , or can be partially or completely halogenated with independent halogen atoms; aryl, heterocyclyl, aryl C 1-4 alkyl, and heterocyclyl C 1-4 alkyl, which can in each case be substituted on the ring or at least on one ring by from one to four substituents R b ; optionally partially or completely halogenated C 1-4 alkoxy, hydroxyl, halogen, nitro, cyano, and NR c 2 when R 12 is bonded to a carbon atom;
or a pharmaceutically acceptable salt thereof.
8. A compound according to claim 7 , wherein Z is C═O, or a pharmaceutically acceptable salt thereof.
9. A compound according to claim 7 , wherein R 1 is H or C 1-4 alkyl, or a pharmaceutically acceptable salt thereof.
10. A compound according to claim 7 , wherein U is S or CR 5 R 6 , wherein R 5 and R 6 are independently selected from H and C 1-4 alkyl, X is CH 2 , or a pharmaceutically acceptable salt thereof.
11. A compound according to claim 7 , wherein Het is isoquinolinyl optionally substituted with a substituent R 11 , wherein R 11 is defined as in claim 7 , or a pharmaceutically acceptable salt thereof.
12. A compound according to claim 7 selected from
6-Isoquinolin-4-yl-3,4-dihydro-1H-quinolin-2-one,
6-Isoquinolin-4-yl-1-methyl-3,4-dihydro-1H-quinolin-2-one,
or a pharmaceutically acceptable salt thereof.
13. A compound of formula (I):
wherein:
Z is C═S;
U is CR 5 R 6 , NR 7 , O or S;
X is CR 5 R 6 , NR 7 , O, or S;
b is 0;
n is 0;
m is 0 or 1;
provided that not more than one of U and X is NR 7 , O, or S;
wherein, when m is 1, the bond between U and X is single bond;
Het is a ring system containing one ring which is aromatic and contains 5 or 6 ring atoms, of which at least one is nitrogen, and the ring system can be substituted by from one to four substituents R 11 ,
R 1 is selected from the group consisting of H; C 1-4 alkyl; C 2-4 alkenyl; C 3-7 cycloalkyl; C 1-4 alkylcarbonyl; and C 1-4 alkoxycarbonyl; each of which can be substituted by from one to three substituents R a , wherein R a is independently selected from the group consisting of optionally partially or completely halogenated C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylthio, and C 1-4 alkylcarbonyl and also hydroxyl, nitro, and cyano, or can be partially or completely halogenated with independent halogen atoms; aryl C 1-4 alkyl and heterocyclyl C 1-4 alkyl, which can in each case be substituted on the ring or at least on one ring by from one to four substituents R b , wherein R b is selected from the group consisting of C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylthio, C 1-4 alkylcarbonyl, C 1-4 alkylsulfonyl, whose alkyl moieties may be partially or completely halogenated with independent halogen atoms, halogen, hydroxyl, nitro, cyano, —NR c 2 , —CONR c 2 , and SO 2 NR c 2 , wherein R c is independently selected from the group consisting of H and C 1-4 alkyl;
R 2 , R 3 and R 4 are independently selected from the group consisting of H, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-7 cycloalkyl, C 5-7 cycloalkenyl, C 1-4 alkoxy, C 1-4 alkylcarbonyl, C 1-4 alkoxycarbonyl, C 1-4 alkylsulfonyl, which in each case can be substituted by from one to three substituents R a , or can be partially or completely halogenated with independent halogen atoms; aryl C 1-4 alkyl, aryl C 0-4 alkylsulfonyl, heterocyclyl C 1-4 alkyl, which can in each case be substituted on the ring or at least on one ring by from one to four substituents R b ; halogen, hydroxyl, nitro, cyano, —NR c 2 , —CONR c 2 , and —SO 2 NR c 2 ;
R 5 and R 6 are independently selected from the group consisting of H, C 1-4 alkyl, C 3-7 cycloalkyl, hydroxyl C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkoxycarbonyl, C 1-4 alkylthio, whose alkyl moieties can be partially or completely halogenated with independent halogen atoms; halogen, hydroxyl, nitro, cyano, —NR c 2 , and NR c COR d , and R d is selected from the group consisting of C 1-4 alkyl, C 3-7 cycloalkyl, C 1-4 alkoxy, whose alkyl moieties can be partially or completely halogenated with independent halogen atoms, and wherein R 5 or R 6 may be bonded to a carbon atom forming part of a double bond,
R 7 is selected from the group consisting of H, C 1-4 alkyl, and C 3-7 cycloalkyl, which in each case can be substituted by from one to three substituents R a , or can be partially or completely halogenated with independent halogen atoms; and aryl C 1-4 alkyl, which can be substituted on the ring or at least on one ring by from one to four substituents R b ;
R 10 is selected from the group consisting of H; C 1-4 alkyl, C 3-7 cycloalkyl, which in each case can be substituted by from one to three substituents R a , or can be partially or completely halogenated with independent halogen atoms; aryl, aryl C 1-4 alkyl, heterocyclyl, and heterocyclyl C 1-4 alkyl, each of which can be substituted on the or at least one ring by from one to four substituents R b ;
R 11 is independently selected from the group consisting of C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-7 cycloalkyl, C 5-7 cycloalkenyl, C 1-4 alkoxy, C 1-4 alkylthio, C 1-4 alkylcarbonyl, C 1-4 alkoxycarbonyl, C 1-4 alkylsulfonyl, which can in each case be substituted by from one to three substituents R a , or can be partially or completely halogenated with independent halogen atoms; aryl, heterocyclyl, aryl C 0-4 alkylsulfonyl, aryl C 1-4 alkyl, and heterocyclyl C 1-4 alkyl, which can in each case be substituted on the ring or at least on one ring by from one to four substituents R b , halogen, hydroxyl, nitro, cyano, —NR c 2 , —CONR c 2 , and —SO 2 NR c 2 ; and
R 12 is independently selected from the group consisting of C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-7 cycloalkyl, C 5-7 cycloalkenyl, which can in each case be substituted by from one to three substituents R a , or can be partially or completely halogenated with independent halogen atoms; aryl, heterocyclyl, aryl C 1-4 alkyl, and heterocyclyl C 1-4 alkyl, which can in each case be substituted on the ring or at least on one ring by from one to four substituents R b ; optionally partially or completely halogenated C 1-4 alkoxy, hydroxyl, halogen, nitro, cyano, and NR c 2 when R 12 is bonded to a carbon atom;
or a pharmaceutically acceptable salt thereof.
14. A compound according to claim 13 , wherein R 1 is H or C 1-4 alkyl, or a pharmaceutically acceptable salt thereof.
15. A compound according to claim 13 , wherein U is S or CR 5 R 6 , wherein R 5 and R 6 are independently selected from H and C 1-4 alkyl, X is CH 2 , or a pharmaceutically acceptable salt thereof.
16. A compound according to claim 13 , wherein Het is for pyridinyl, pyrimidinyl or imidazolyl, optionally substituted with a substituent R 11 , wherein R 11 is defined as in claim 12 , or a pharmaceutically acceptable salt thereof.
17. A compound according to claim 13 selected from
8-Chloro-6-pyridin-3-yl-3,4-dihydro-1H-quinoline-2-thione,
8-Fluoro-6-pyridin-3-yl-3,4-dihydro-1H-quinolin-2-thione,
7-Fluoro-6-pyridin-3-yl-3,4-dihydro-1H-quinolin-2-thione,
or a pharmaceutically acceptable salt thereof.